Stocks · Theme
Cardiovascular therapeutics stocks · 7 research notes
7 Cardiovascular therapeutics stocks moving on the same story, each with a dated research note: thesis, kill line and next catalyst.
Active themeTracked as of 11 November 2026.
All 7 have a dated research note with a published kill line: the note's own test, stated in advance, of what would prove it wrong: a price level, a business fact, or both.
All stocksKNSAKiniksa Pharmaceuticals InternationalMedium Kiniksa Pharmaceuticals is modestly more likely than not to beat the S&P 500 over three months on its third 2026 ARCALYST guidance raise, to $1.045–1.050 billion. Fourth-quarter sales and the first 2027 range, due in the early-2027 results…AMGNAmgenMedium Amgen is modestly more likely than not to beat the S&P 500 over three months because Repatha, Evenity and newer drugs are outgrowing biosimilar losses. The fourth-quarter report and 2027 outlook, expected in early February 2027, settle it.LQDALiquidiaMedium Liquidia Corporation's shares are modestly more likely to beat the S&P 500 because YUTREPIA sales rose 31% to $222.7 million in the third quarter with record October shipments; preliminary fourth-quarter sales, due in early January 2027,…CRSPCRISPR TherapeuticsLow CRISPR Therapeutics shares are more likely to lag the S&P 500 over three months: they hit a 52-week closing low of $42.62 on 12 November 2026 despite strong CTX310 data, and December's zugo-cel data at ASH is the next test.EWTXEdgewise TherapeuticsMedium Edgewise Therapeutics is modestly more likely than not to beat the S&P 500 over three months: FDA-cleared Phase 3 plans for heart drug EDG-7500, $1.74 billion of cash and unconfirmed takeover reports support it. The STRATUS-HCM trial…CRDLCardiol TherapeuticsLow Cardiol Therapeutics is more likely to lag the S&P 500 over three months: the MAVERIC Phase III topline is guided for mid-2027, and the company has begun selling stock under a US$75 million at-the-market program. That readout settles the…IKTInhibikase TherapeuticsLow Inhibikase Therapeutics' IKT-001 for pulmonary arterial hypertension is funded, with $193.3M cash on 30 September 2026, but dilution and warrant-dependent runway weigh on shares at $1.55; 2027 interim safety data is next.